Fig. 1From: Targeting the GPR119/incretin axis: a promising new therapy for metabolic-associated fatty liver diseaseTissue distribution of GPR119. GPR119 may be present in the brain, gastrointestinal digestive system, pancreas, liver, and heart, but there is still controversy (indicated with question marks in the figure). The reason may be low expression or differences in detection methods. In the future, some strict detections are still neededBack to article page